Oncogenomics

Caidya Welcomes Jay Roberts to its Board of Directors

Retrieved on: 
Wednesday, January 3, 2024
Drug discovery, Physician, Hospital, Strategic planning, Oncogenomics, CNS, Growth, Patient, Pharmaceutical industry

MORRISVILLE, N.C. and SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Caidya, a leading multi-therapeutic clinical research organization (CRO), is pleased to announce the appointment of Jay Roberts to its Board of Directors.

Key Points: 
  • MORRISVILLE, N.C. and SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Caidya, a leading multi-therapeutic clinical research organization (CRO), is pleased to announce the appointment of Jay Roberts to its Board of Directors.
  • Jay Roberts appointed to global clinical research organization (CRO) Caidya's Board of Directors.
  • Roberts is a seasoned executive with a proven track record of building successful emerging growth-oriented companies in the life sciences sector.
  • "We are thrilled to have Jay join our Board of Directors and bring his extensive experience and leadership in the biopharmaceutical industry," said Lingshi Tan, Ph.D., Chairman and CEO of Caidya.

Caidya Welcomes Jay Roberts to its Board of Directors

Retrieved on: 
Wednesday, January 3, 2024
Drug discovery, Physician, Hospital, Strategic planning, Oncogenomics, CNS, Growth, Patient, Pharmaceutical industry

MORRISVILLE, N.C. and SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Caidya, a leading multi-therapeutic clinical research organization (CRO), is pleased to announce the appointment of Jay Roberts to its Board of Directors.

Key Points: 
  • MORRISVILLE, N.C. and SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Caidya, a leading multi-therapeutic clinical research organization (CRO), is pleased to announce the appointment of Jay Roberts to its Board of Directors.
  • Roberts is a seasoned executive with a proven track record of building successful emerging growth-oriented companies in the life sciences sector.
  • "We are thrilled to have Jay join our Board of Directors and bring his extensive experience and leadership in the biopharmaceutical industry," said Lingshi Tan, Ph.D., Chairman and CEO of Caidya.
  • With a strong focus on customer experience and delivery excellence, Caidya is dedicated to bringing life-changing therapies to patients worldwide.

The New York Genome Center Launches the MacMillan Center for the Study of the Non-Coding Cancer Genome

Retrieved on: 
Thursday, January 19, 2023
Genome, Cell, Element, Metastasis, FRSC, Biomedical Research, DNA, Computational biology, Precision medicine, Breast, Mathematics, Ovary, Transcriptome, Lung, Causality, MacMillan Center for International and Area Studies, Drug resistance, Education, Hematological Cancer Research Investment and Education Act, Proteome, Columbia University, Weill Cornell Medicine, Diagnosis, New York Genome Center, Genomics, Engineering, RNA, Biology, Research, Cancer, Epigenome, Morehouse School of Medicine, Cold Spring Harbor Laboratory, Royal College of Pathologists, Pancreas, Behavior, Memorial Sloan Kettering Cancer Center, Doctor of Philosophy, Northwell Health, Pharmaceutical industry, Management, Vaccine, Oncogenomics, New York University

NEW YORK, Jan. 19, 2023 /PRNewswire/ -- The New York Genome Center (NYGC) announced the launch of the MacMillan Center for the Study of the Non-Coding Cancer Genome (MCSNCG) today, a major new initiative in cancer research to study the role and function of the non-coding genome and epigenome in the evolution, progression, and treatment of multiple cancer types, including breast, ovary, pancreas, gastrointestinal, lung, and hematologic cancers.

Key Points: 
  • The non-coding "dark" genome constitutes 98% of the human genome and it plays an essential regulatory role across all molecular layers of biological complexity (i.e.
  • genome, epigenome, transcriptome, proteome), influencing DNA organization and structure, genome accessibility to regulatory proteins and RNA, and intracellular organelle organization.
  • Therefore, foundational questions regarding the role of the non-coding genome in the development and progression of many cancer types remain unanswered.
  • Samuel Aparicio, FRCPath PhD, FRSC, NYGC's Senior Scientific Director of Cancer Genomics, says, "Decoding causality is fundamental to providing interpretable quantitative explanations of elements of the non-coding genome in cancer.

BLACKSMITH MEDICINES ANNOUNCES ONCOLOGY SCIENTIFIC ADVISORS

Retrieved on: 
Thursday, January 5, 2023
Head, British Biotech, DNA, Science, SAN, Metalloprotein, Institute of Cancer Research, Genetics, BRCA, Blacksmith, Pharmaceutical industry, Chemistry, Oncogenomics

SAN DIEGO, Jan. 5, 2023 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, today announced additions to its science advisory team to help advance its emerging precision oncology programs focused on novel synthetic lethality targets involved in the DNA Damage Response.

Key Points: 
  • SAN DIEGO, Jan. 5, 2023 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, today announced additions to its science advisory team to help advance its emerging precision oncology programs focused on novel synthetic lethality targets involved in the DNA Damage Response.
  • Additions to Blacksmith's oncology scientific advisors include:
    Jeff Hager, Ph.D.
  • Former Evotec Head of Oncology and Director of Chemistry at British Biotech
    "We are honored to work with such an outstanding group of biotechnology leaders on our oncology scientific advisors board, who share our passion to develop novel medicines against undrugged metalloenzyme targets with next-generation chemistries," said Zachary Zimmerman, Ph.D., CEO and co-founder of Blacksmith.
  • We look forward to their contributions as we grow Blacksmith and expand on our capabilities in precision oncology."

Multi-Center Research Study Illustrates How OGM Can Potentially Result in More Patients Qualifying for Treatments in Leukemia

Retrieved on: 
Friday, December 9, 2022
SNV calling from NGS data, Oncogenomics, Autism, Diagnosis, CMA, Chromosome, Hospital Insurance and Diagnostic Services Act, Annual report, In situ hybridization, Medicine, International Cancer Genome Consortium, Lineagen, Software, Security (finance), TP53, Marie Cassidy, KT, Karyotype, National Comprehensive Cancer Network, ELN, Doctor of Philosophy, NCCN, Fluorescence, AML, Acute myeloid leukemia, SVS, Patient, OGM, Research, Pathology, Standard of care, Genome, Genomics, Biology, WHO, COVID-19, World Health Organization, CNV, Dietary supplement, Pharmaceutical industry, Medical imaging, FISH

The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.

Key Points: 
  • The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.
  • The Company offers OGM solutions for applications across basic, translational and clinical research.
  • Bionano’s OGM products are for research use only and not for use in diagnostic procedures.
  • We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Haystack Oncology Appoints Joel Kaufman as Chief Financial Officer

Retrieved on: 
Thursday, December 1, 2022
Growth, Management, CFO, Johns Hopkins University, Kellogg School of Management, University, Blood, DNA, Multimedia, Corporation, Technology Center, Oncogenomics, Circulating tumor DNA, MBA, Patient, Health technology, Goldman, Noise, Hay, Neoplasm, MRD, Liquid biopsy, Secondary research, Goldman Sachs, The Garage at Northwestern University, Medical imaging, Pharmaceutical industry, MD

BALTIMORE, Dec. 1, 2022 /PRNewswire/ -- Haystack Oncology ("Haystack"), an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology to optimize minimal residual disease (MRD) testing and better inform decisions around therapy, today announced the appointment of Joel Kaufman as Chief Financial Officer.

Key Points: 
  • BALTIMORE, Dec. 1, 2022 /PRNewswire/ -- Haystack Oncology ("Haystack"), an oncology company that applies the next generation of circulating tumor DNA (ctDNA) detection technology to optimize minimal residual disease (MRD) testing and better inform decisions around therapy, today announced the appointment of Joel Kaufman as Chief Financial Officer.
  • Mr. Kaufman joins Haystack with over a decade of experience spanning business development, investment banking and finance.
  • Mr. Kaufman will lead Haystack's financial operations and implement strategic initiatives to support the commercialization of the company's best-in-class MRD assay.
  • Previously, Mr. Kaufman spent nearly four years in multiple roles, culminating in Chief Business Officer, at Navidea Biopharmaceuticals.

AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

Retrieved on: 
Tuesday, September 6, 2022
COVID-19, Lists of diseases, NYSE, Roswell Park Comprehensive Cancer Center, Research, AIM, Oncogenomics, Disease, Board, Rintatolimod, Pharmacology, Degenerative disease, GLOBE, Company, Therapy, Immune system, Cancer, American, Pharmaceutical industry

Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022.

Key Points: 
  • Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022.
  • In addition to managements presentations, the Company is proud to announce its sponsorship of the event.
  • Presentations will take place at the Cancer Genetics & Pharmacology Building at the Roswell Park Comprehensive Center.
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.

Nonacus Welcomes Two Senior Leadership Hires: Dr Andy Feber and Dr Samuel Clokie

Retrieved on: 
Wednesday, August 17, 2022
Genomics, Machine learning, Royal Marsden Hospital, Genetic testing, Precision medicine, University of Dundee School of Medicine, NIH, CEO, Division, Cancer Research UK, Diagnosis, Technology, Cancer, Research, Bioinformatics, Oncogenomics, Institute, Patient, DNA, Translation, Associate, Doctor of Philosophy, RNA-Seq, Artificial intelligence, Workflow, University, University College London, Liquid biopsy, Development, Dietary supplement, Medical imaging, Circadian rhythm, Biochemistry

BIRMINGHAM, England, Aug. 17, 2022 /PRNewswire/ -- Nonacus Ltd, leading provider of genetic testing products for precision medicine and liquid biopsy, is very pleased to announce the appointment of two senior leadership hires: Dr Andy Feber as Clinical Directorof Research and Development and Dr Samuel Clokie as Director of Bioinformatics & Data Science.

Key Points: 
  • BIRMINGHAM, England, Aug. 17, 2022 /PRNewswire/ -- Nonacus Ltd, leading provider of genetic testing products for precision medicine and liquid biopsy, is very pleased to announce the appointment of two senior leadership hires: Dr Andy Feber as Clinical Directorof Research and Development and Dr Samuel Clokie as Director of Bioinformatics & Data Science.
  • CEO of Nonacus, Chris Sale commented, "Our technology has now been proven in the liquid biopsy translational research and clinical setting.
  • Sam's responsibilities will encompass Bioinformatics team leadership and developing bioinformatic data analysis strategies to align with Nonacus' strategic objectives.
  • Nonacus provides a complete workflow for liquid biopsy analysis with the goal of enabling better cancer care through earlier diagnosis, treatment stratification and monitoring.

DermTech Appoints Chief Compliance Officer and SVP of Research and Development

Retrieved on: 
Thursday, July 28, 2022
Biotechnology, General Health, Health, Genetics, Oncology, Association, Civil and political rights, Inflammation, University, Skin, Registered, Genomics, HHS, Food and Drug Administration, United States Department of Justice Antitrust Division, Dermatology, U.S. Securities and Exchange Commission, CEO, SEC, Centers for Medicare & Medicaid Services, Drug Enforcement Administration, Myriad Genetics, Research, Prostate cancer, Solution, Compliance, Private Securities Litigation Reform Act, Board, The Florida Bar, NASDAQ, PBM, American Health Lawyers Association, Adoption, Myriad, BRCA1, FDA, Security (finance), Federal Trade Commission, Smart, Patient, Record, Department, Justice, Annual report, Medicare, Medicine, Management, Pharmaceutical industry, Oncogenomics, Genetics

Jennifer Eilemberg has been named chief compliance officer and will oversee the Companys compliance with laws, regulatory requirements, rigorous internal policies and procedures.

Key Points: 
  • Jennifer Eilemberg has been named chief compliance officer and will oversee the Companys compliance with laws, regulatory requirements, rigorous internal policies and procedures.
  • Jennifer and Steve both have excellent track records in their respective professions and were thrilled to have them on our team.
  • She has also served as general counsel and chief compliance officer for several healthcare companies.
  • He was previously the vice president of Kidney Care at CareDx, leading a team that oversaw the research and development of several kidney care test offerings.

ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors

Retrieved on: 
Tuesday, April 12, 2022
Oncogenomics, Board, Spiritual Ambassador program, ALX, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, Microdeletion syndrome, U.S. Securities and Exchange Commission, Security (finance), Research, Board of directors, HBA, Doctor of Philosophy, GLOBE, University of Mainz, Patient, FC, SAN, CD47, Bayer, Lymphatic system, SEC, Forward-looking statement, Health care, Organization, University, Acute myeloid leukemia, Cancer, Medical imaging, Biology

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors (the Board) effective April 11, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors (the Board) effective April 11, 2022.
  • We are excited to welcome Dr. Canamasas to our Board during an important time in ALX Oncologys continued evolution, said Corey Goodman, Ph.D., Executive Chairman of ALX Oncology.
  • Dr. Canamasas provides a proven track record of successful oncology product launches and transformational strategic expertise to ALX Oncology that will be instrumental in 2022 and beyond as we execute on helping patients fight cancer.
  • I am excited to join the Board at this pivotal junction in ALX Oncologys growth trajectory.